StockData

Aligos Therapeutics vs Prime Medicine

ALGS and PRME side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ALGS and PRME compare

Prime Medicine is the larger company, worth 29 times as much as Aligos Therapeutics ($780M against $27.0M).

Aligos Therapeutics scores higher on the StockData Score (7 against 5 for Prime Medicine), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricALGSPRME
Size and price
Market cap$27.0M$780M
Share price$2.16$4.30
Change, 1 year−68.6%22.0%
Change, 5 years−99.5%−79.6%
Beta (5Y)1.510.43
Employees82146
StockData Score
Total score7 (better)5
Valuation score1 (better)0
Growth score1 (better)0
Performance score00
Health score55
Dividend score00
Valuation
P/S4.6×–
P/B2.4× (better)19.6×
FCF yield–−20.1%
Fair value$2.40–
Margin of safety9.8%–
Growth
Revenue growth (TTM)122%–
Revenue growth, 5Y average–−2.3%
Profitability
Operating margin−1244%–
Net margin−1137%–
Return on equity−159% (better)−373%
Financial health
Debt / equity0.000.00
Current ratio1.773.05 (better)
Altman Z-score−24.54−5.56 (better)
Piotroski F-score44
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions18.4%58.8%
Held by insiders–18.6%
Superinvestors holding1–
Short interest, % of float–19.7%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.